Menu
J Clin Aesthet Dermatol. 2021;14(2):22–24. by Rym Afiouni, MD; Josiane Helou, MD; Stephanie Matar, MD; and Roland Tomb, MD, PhD All authors are with the Department of Dermatology, Hôtel-Dieu de France University Hospital, Saint Joseph University in Beirut, Lebanon. FUNDING: No funding was provided for this article. DISCLOSURES: The authors report no conflicts of interest
J Clin Aesthet Dermatol. 2021;14(2):12–13. Dear Editor: In their recent article, Lowery et al1 argue that iPLEDGE should remove abstinence as a contraceptive method, requiring individuals with reproductive potential to instead use medical contraception, regardless of sexual activity. We feel this change would be unlikely to significantly reduce fetal isotretinoin exposure, raises unacceptable ethical concerns,
J Clin Aesthet Dermatol. 2021;14(2):12–13. Dear Editor: iPLEDGE, the risk evaluation and mitigation strategy program for isotretinoin, has been criticized for being unnecessarily complex, antiquated, and ineffective. It mandates that those with ovaries and a uterus who are premenopausal either take two forms of contraception or sign an abstinence pledge when starting isotretinoin. In a
Dear Editor: There is no doubt now that the use of botulinum toxin (BoNT) in aesthetics has been a revolution for the noninvasive treatment of patients. In the last several decades, the use of BoNT has changed from fixed doses delivered at fixed time intervals into fixed anatomical sites, all of which were required for
J Clin Aesthet Dermatol. 2021;14(1):14–20. by Clinton W. Enos, MD; Soquel Rey, BS; Jayne Slocum, BS; Lauren Green, MPH; and Edward Prodanovic, MD Dr. Enos, Dr. Prodanovic, Mr. Rey, and Ms. Slocum are with the Department of Dermatology, Eastern Virginia Medical School in Norfolk, Virginia. Ms. Green is with the Healthcare Analytics and Delivery Science
